Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 4, 2008, Pages

  Bedard, Philippe L ^a   Piccart Gebhart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant chemotherapy; Bevacizumab; Cardiac toxicity; Lapatinib; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHROMOSOME 17; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE NUMBER; HEART DISEASE; HEART FAILURE; HUMAN; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; OVERALL SURVIVAL; PATIENT SELECTION; PROTEIN EXPRESSION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; BREAST TUMOR; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; METASTASIS; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 60849094827     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.s.012     Document Type: Article

References (65)

1. Sledge GW. Targeting HER2 in the adjuvant setting. Presented at: the 2005 American Society of Clinical Oncology Annual Meeting; May 13-17, 2005; Orlando, FL.
2. Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008; 13:620-30.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med 2005; 353:1673-84.
4. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25(18 suppl):6s (Abstract 512).
5. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94:852-4.
6. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94855-7.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New Eng J Med 2005; 353:1659-72.
8. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 36929-36.
9. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at: the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 52.
10. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Eng J Med 2006; 354:809-20.
11. Saez A, Andreu FJ, Segui MA, et al. HER2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Breast 2006; 15:519-27.
12. Spielmann M, Roché H, Humblet Y, et al. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 72.
13. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti- p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-44.
14. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26.
15. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48.
16. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93:3-11.
17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Eng J Med 2001; 344:783-92.
18. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastu-zumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642-9.
19. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45.
20. Trastuzumab (Herceptin) [package insert]. 2008. Available at: http://www.gene.com/ gene/products/information/pdf/herceptin-prescribing.pdf. Accessed: July 2, 2008.
21. Wolff AC, Paik S, Press M F. HER2 as a predictive marker: why bother testing? In: Govindan R, ed. American Society of Clinical Oncology 2008 Annual Meeting Education Book. Alexandria, VA: American Society of Clinical Oncology; 2008:25-8.
22. McCaskill-Stevens W, Procter M, Goodbrand J. Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 709.
23. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. New Eng J Med 2008; 358:1409-11.
24. Kaufman PA, Broadwater G, Lezon-Geyda K, et al. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC). J Clin Oncol 2007; 25(18 suppl):34s (Abstract 1009).
25. McCaskill-Stevens W, Procter M, Goodbrand J, et al. Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial. Breast Cancer Res Treat 2007; 106 (suppl 1):S18 (Abstract 71).
26. Reinholz M, Jenkins R, Hillman D, et al. The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 36.
27. Peto R. Early Breast Cancer Trialists' Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. In: San Antonion Breast Cancer Symposium 2007, Abstract P-1; 2007.
28. Von Hoff DD, Layard M W, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-7.
29. Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006; 17:85-92.
30. Levine MN, Pritchard KI, Bramwell VHC, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, metho-trexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23:5166-70.
31. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
32. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study. J Clin Oncol 2005; 23:8597-605.
33. Giordano SH, Duan Z, Kuo Y-F, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24:2750-6.
34. Gennari A, Sormani M P, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100:14-20.
35. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820-6.
36. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). J Clin Oncol 2007; 25(18 suppl):6s (Abstract LBA513).
37. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-65.
38. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. New Eng J Med 2007; 357:94-5.
39. Montemurro F, Redana S, Valabrega G, et al. Trastuzumab-related cardiotoxicity in the Herceptin Adjuvant Trial. J Clin Oncol 2008; 26:2052-3.
40. Timolati F, Ott D, Pentassuglia L, et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J MolCell Cardiol 2006; 41:845-54.
41. Di Leo A, Licitra S, Claudino W, et al. Molecular predictors of response to anthracy-clines. In: Govindan R, ed. American Society of Clinical Oncology 2008 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2008:3-7.
42. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis. Presented at: the 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX. Abstract 1.
43. Slamon D, Eirmann W, Robert N, et al. BCIRG 066: Second interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006; 100(suppl 1) Abstract 52.
44. Slamon D, Mackey J, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 13.
45. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001; 358:439-44.
46. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26:1231-8.
47. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000; 27:21-5; discussion 92-100.
48. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889-95.
49. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19:1090-6.
50. Tannock I F. From evidence-based medicine to clinical practice: not always straightforward. Eur J Cancer 2003; 1:93-101.
51. Leyland-Jones B, Gelmon K, Ayoub J P, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21:3965-71.
52. Clinicaltrials.gov [Web site]. The Synergism Or Long Duration (SOLD) study NCT00593697. Available at: http://clinicaltrials.gov/ct2/show/NCT00593697? t erm=Synergism+Or+Long+Duration&rank=1. Accessed: July 4, 2008.
53. Clinicaltrials.gov [Web site]. Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. Available at: http://clinicaltrials.gov/ct2/show/NCT00381901?term= PHARE&rank=1. Accessed: July 4, 2008.
54. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as firstline therapy for erbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26:2999-3005.
55. O'Shaughnessy J, Blackwell KL, Burstein HS, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008; 26(15 suppl):44s (Abstract 1015).
56. Clinicaltrials.gov [Web site]. Tykerb evaluation after chemotherapy (TEACH): lapatinib versus placebo in women with early-stage breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00374322?term= teach&rank=5. Accessed July 7, 2008.
57. GSK reports Q1 Business Performance EPS of 25.6p. 2008. Available at: http:// www.gsk.com/investors/reports/q12008/q12008.pdf. Accessed: July 28, 2008.
58. Clinialtrials.gov [Web site]. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) study; BIG 2-06/N063D. Available at: http://clinicaltri-als.gov/show/NCT00490139. Accessed: December 2, 2008.
59. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26(15 suppl):43s (Abstract LBA1011).
60. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 2007; 357:2666-76.
61. Pegram M, Chan D, Dichmann R, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Presented at: the 26th Annual San Antonio Breast Cancer Symposium; December 17, 2006; San Antonio, TX. Abstract 301.
62. Clinicaltrials.gov [Web site]. BETH study: treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastu-zumab plus bevacizumab. Available at: http://clinicaltrials.gov/ct2/show/ record/ NCT00625898. Accessed: July 7, 2008.
63. Clinicaltrials.gov [ Web site]. Neo ALT TO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. Available at: http://clinicaltrials. gov/ct2/show/NCT0 0553358?cntry1=SS%3APK&rank=35. Accessed: December 2, 2008.
64. Clinicaltrials.gov [Web site]. Paclitaxel and trastuzumab and/or lapatinib in treating patients with stage II or stage III breast cancer that can be removed by surgery. Available at: http://clinicaltrials.gov/ct2/show/ NCT00770809?term=CALGB+40 601&rank=1. Accessed: December 2, 2008.
65. Clinicaltrials.gov [Web site]. A Study of AC followed by a combination of pacli-taxel plus trastuzumab or lapatinib or both given before surgery to patients with operable HER2 positive invasive breast cancer. Available at: http://clinicaltrials. gov/ct2/show/NCT00486668?term=NSABP+B-41&rank=1. Accessed: December 2, 2008.